

## TUMOR-RESTRICTED DELIVERY OF AN IMMUNE-THERAPEUTIC PAYLOAD BY MODIFIED MACROPHAGES FOR THE TREATMENT OF GLIOBLASTOMA: THE TEM-GBM STUDY (NCT03866109)

1. Hematology and Bone Marrow Transplant Unit - San Raffaele Hospital - Milano; 3. Centre Hospitalier Université de Lausanne-Losanna; 4. Neuro-Oncology Unit - Istituto Neurologico Carlo Besta - Milano; 5. Neurosurgery Unit - Policlinico Gemelli - Roma; 6. Neurosurgery Unit - Istituto Neurologico Carlo Besta - Milano; 7. Neurosurgery Unit - San Raffaele Hospital - Milano;



F. Ciceri<sup>1</sup>, B. Gentner<sup>2,3</sup>, A. Capotondo<sup>2</sup>, M. Eoli<sup>4</sup>, F. Farina<sup>1</sup>, G. D'Alessandris<sup>5</sup>, F. Di Meco<sup>6</sup>, Ferla V<sup>1</sup>, F. Farina<sup>1</sup>, G. Bilini<sup>5</sup>, M. Saini<sup>6</sup>, S. Snider<sup>8</sup>, L. Naldini<sup>2</sup>, C. Russo<sup>10</sup>, G. Finocchiaro<sup>11</sup>





azard ratio 5% CI)	Median (months; 95% CI)	2 years (%)	3 years (%)	4 years (%)	5 years (%)			
0	11.8 (10.0–14.4)	1.8 (0.1–8.6)	0	0	0			
6 (0·4–0·8)	12.6 (11.6–14.4)	14.8 (7.2–25.0)	11.1 (4.7–20.7)	11.1 (4.7–20.7)	8.3 (2.7–18.0)			
5 (0·3–0·7)	15·3 (13·0–20·9)	23.9 (12.9–36.9)	7.8 (2.2–18.3)	7·8 (2·2–18·3)	5.2 (1.0–15.0)			
3 (0·2–0·4)	23.4 (18.6–32.8)	48.9 (33.7–62.4)	27.6 (15.4–41.4)	22.1 (11.0-35.7)	13.8 (4.5–28.2)			
less otherwise stated. *HR relative to radiotherapy unmethylated.								

NALYSIS AFTE	OF 2 <sup>ND</sup> SURGERY 1 R TEMFERON ADM	TUMOR SPECIMENS
TUMOR 045+	2 <sup>nd</sup> SURGERY FROM DIAGN/TEMF	SURVIVAL FROM DIAGN/TEMF
na	12/8.6 mths	25/21 mths
na	7.5/4 mths	19/16 mths
5%	10/6.7 mths	15/11 mths
na	8/3.9 mths	14/11 mths
3%	17/14 mths	28.5/26.5 mths
na	14/11 mths	18/14 mths
= Diagnosis		Censored 30 <sup>th</sup> June 2023

		% <b>(</b>		
		100		_
	> LLOQ	75		_
	ith IFN- $\alpha$	50		_
	of Pts w	25		_
	%			
		0 _	0/4 0/12	
		0 _	0/4 0/12 Scr/Bas	D
Cer	nsor	• _	0/4 0/12 Scr/Bas Low	20
Cer	nsor	° _	0/4 0/12 Scr/Bas Low	20
Cer	D	° -	o/4 o/12 Scr/Bas Low	200 <b>r</b>
		% of Pts with IFN-α > LLOQ	100 50 Valie Val	Sol P1   100   75   50   50   25

of IFN- $\alpha$  in the CSF increases accordingly to the dose cohort and with time in most the patients

# • Rapid engraftment and **hematological recovery** observed in all patients treated • Temferon-derived differentiated cells were evident within the peripheral blood • The frequency of peripherally expanded clones found in the tumor samples increases by the second surgery, as evidence of a notable crosstalk between